Novus Biologicals Announces New ROBLD3 Antibody made using SDIX Genomic Antibody Technology™
November 9,
2011
Novus Biologicals Announces New ROBLD3
Antibody made using SDIX Genomic Antibody Technology™
Novus Biologicals
announced today a new ROBLD3 antibody (catalog number NBP1-71687) for use in research on cell growth regulation. This ROBLD3
antibody was made using SDIX Genomic Antibody Technology.
ROBLD3 is one of three individual proteins (ROBLD3, c11orf59
& MAPKSP1) that form the Ragulator Complex. This complex is a
fundamental component of the TORC1 signaling pathway, which begins the
signaling cascade for cell growth regulation. ROBLD3 antibody studies have
indicated that insulin stimulation may augment mTORC1 activity via a parallel
pathway.
Individually, the three Ragulator proteins have
increasingly become the focus of research on cell growth regulation, as well as
the insulin stimulated and TORC1 parallel signaling pathways. Novus now offers
quality guaranteed antibodies to all three Ragulator components, including a
new highly-specific ROBLD3 antibody (NBP1-71687).
SDIX Genomic Antibody Technology™ uses sophisticated
bioinformatics and immunization strategies to produce high-quality antibodies
that specifically bind to a targeted region of protein in its naturally folded
form. The ability of any antibody to recognize a protein’s naturally folded
state has the potential to expand an antibody’s utility to high-value
applications like sandwich immunoassay, ChIP and flow
cytometry. Learn more about SDIX Genomic Antibodies by reading
the SDIX Genomic Antibody
FAQ or by downloading theSDIX Genomic Antibody White Paper.
About Novus Biologicals (www.novusbio.com)
Novus Biologicals is a biotechnology company whose mission is to
accelerate scientific discovery by developing and marketing unique products in
the forefront of science. Novus Biologicals provides primary
antibodies, secondary antibodies, conjugated antibodies, proteins, peptides,
isotype and loading controls, RNAi, lysates, stem cell lines and antibody
labeling kits to the bioscience community. All of Novus' products
are 100% guaranteed to work in the species and applications listed on the
datasheet. By serving niche and emerging markets, Novus Biologicals
has formed and will continue to form ongoing partnerships with leading
researchers.
About SDIX (www.sdix.com)
SDIX is a biotechnology company with a core expertise at
creating better antigens, better antibodies and better assays for the
pharmaceutical, biotechnology and food safety markets. For over 20 years, SDIX
has been a leading immuno-solutions Company, developing results-oriented and
innovative antibody-based solutions that enable customers to meet high performance
research, diagnostic and commercialization objectives.
In the life science market, SDIX’s technology and
capabilities are being used to help discover disease mechanisms, facilitate
development of new drugs, and provide antibodies and assays for the diagnosis
of disease. In the food safety market, SDIX continues to expand its
footprint as an international supplier of rapid pathogen test technologies that
enable more accurate and cost effective results.
This news release may contain forward-looking statements
reflecting SDIX's current expectations. When used in this press release, words
like “anticipate”, “could”, “enable”, “estimate”, “intend”, “expect”,
“believe”, “potential”, “will”, “should”, “project”, “plan” and similar
expressions as they relate to SDIX are intended to identify said
forward-looking statements. Investors are cautioned that all forward-looking
statements involve risks and uncertainties, which may cause actual results to
differ from those anticipated by SDIX at this time. Such risks and
uncertainties include, without limitation, changes in demand for products, the
application of our technologies to various uses, delays in product development,
delays in market acceptance of new products, retention of customers and
employees, adequate supply of raw materials, inability to obtain or delays in
obtaining fourth party or required government approvals, the ability to meet
increased market demand, competition, protection of intellectual property,
non-infringement of intellectual property, seasonality, and other factors more
fully described in SDIX's public filings with the U.S. Securities and Exchange
Commission.
About SDIX
SDIX is a biotechnology
company with a core expertise in creating better antigens, better
antibodies and better assays for the pharmaceutical, biotechnology and
food safety markets. For over 20 years, SDIX has been a leading
immuno-solutions company, developing results-oriented and innovative
antibody-based solutions that enable customers to meet high performance
research, diagnostic and commercialization objectives.
In
the life science market, SDIX’s technology and capabilities are being
used to help discover disease mechanisms, facilitate development of new
drugs and provide antibodies and assays
for the diagnosis of disease. In the food safety market, SDIX continues
to expand its footprint as an international supplier of rapid pathogen
test technologies that enable more accurate and cost-effective results.
Media Contact
Media Relations
mediarelations@sdix.com
SDIX
111 Pencader Drive
Newark, DE 19702
302-456-6789